Neurocrine Biosciences, Inc. (NBIX) Insider Sells $157,053.44 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Darin Lippoldt sold 1,979 shares of the business’s stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $79.36, for a total value of $157,053.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Darin Lippoldt also recently made the following trade(s):

  • On Friday, December 28th, Darin Lippoldt sold 15,237 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $75.00, for a total value of $1,142,775.00.
  • On Thursday, December 28th, Darin Lippoldt sold 15,237 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $75.00, for a total value of $1,142,775.00.
  • On Friday, December 8th, Darin Lippoldt sold 2,955 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $75.00, for a total value of $221,625.00.
  • On Monday, December 4th, Darin Lippoldt sold 6,279 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $75.04, for a total value of $471,176.16.
  • On Wednesday, November 15th, Darin Lippoldt sold 9,900 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $73.05, for a total value of $723,195.00.

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) traded down $2.70 during trading on Thursday, reaching $80.28. The company’s stock had a trading volume of 1,134,136 shares, compared to its average volume of 1,234,167. The company has a market capitalization of $7,110.00, a PE ratio of -36.16 and a beta of 0.35. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences, Inc. has a 52-week low of $38.43 and a 52-week high of $83.57.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.36. The business had revenue of $60.77 million during the quarter, compared to the consensus estimate of $29.38 million. During the same period in the prior year, the company posted ($0.43) earnings per share. analysts expect that Neurocrine Biosciences, Inc. will post -1.66 EPS for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the company. First Trust Advisors LP boosted its position in shares of Neurocrine Biosciences by 29.0% in the third quarter. First Trust Advisors LP now owns 782,685 shares of the company’s stock valued at $47,963,000 after acquiring an additional 176,136 shares during the period. Davidson Kempner Capital Management LP bought a new stake in shares of Neurocrine Biosciences in the second quarter valued at approximately $3,639,000. Janus Henderson Group PLC boosted its position in shares of Neurocrine Biosciences by 2.6% in the third quarter. Janus Henderson Group PLC now owns 5,507,763 shares of the company’s stock valued at $337,516,000 after acquiring an additional 140,639 shares during the period. Artisan Partners Limited Partnership bought a new stake in shares of Neurocrine Biosciences in the second quarter valued at approximately $15,981,000. Finally, State Street Corp boosted its position in shares of Neurocrine Biosciences by 5.1% in the second quarter. State Street Corp now owns 2,710,196 shares of the company’s stock valued at $124,666,000 after acquiring an additional 131,141 shares during the period.

Several brokerages recently commented on NBIX. BidaskClub raised Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday. Oppenheimer set a $85.00 price target on Neurocrine Biosciences and gave the company a “buy” rating in a research note on Tuesday, December 12th. Robert W. Baird reissued a “buy” rating and issued a $84.00 price target on shares of Neurocrine Biosciences in a research note on Friday, November 3rd. Needham & Company LLC reissued a “buy” rating and issued a $86.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Finally, Barclays boosted their price target on Neurocrine Biosciences from $75.00 to $85.00 and gave the company an “overweight” rating in a research note on Thursday, November 2nd. One equities research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $78.88.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://transcriptdaily.com/2018/01/05/neurocrine-biosciences-inc-nbix-insider-sells-157053-44-in-stock.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply